Founded in 2017, Priavoid GmbH is headquartered in Jülich, near Düsseldorf, Germany.
Priavoid is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS).
We develop novel therapies for the treatment of neurological diseases based on all-D-peptides. The most advanced drug in our pipeline is PRI-002, a Phase I clinical trial candidate for the treatment of Alzheimer’s disease. The treatment strategy of PRI-002 differs from conventional approaches in that the so-called “toxic oligomers” – that is the probable cause of the neurodegenerative disease – are eliminated in the presence of the drug candidate. The oral administration of PRI-002 leads to improved cognitive behavior in three different transgenic mouse models.
Priavoids aim is to become a leading Central Nervous System (CNS) development company.
Our global growth strategy has three elements, centered around developing innovative therapies for CNS disorders, with a particular focus on drugs for treatment of Alzheimer’s diseases.
1. Maximize PRI-002 commercial opportunity
We are working to maximize the opportunity for PRI-002, which as the first causal therapy to treat Alzheimer’s disease has the potential to improve the lives of patients around the world. After successfully completing a Phase I clinical trial, we plan to conduct a Phase II clinical trial.
2. Focus development resources on value-creation
To maximize the value of our pipeline, we are utilizing our development resources on our portfolio of CNS drugs. Developing CNS candidates matches best the company’s organizational resources, and allows us to generate substantial benefit for patients suffering from these diseases.
3. Out license or monetize non-core assets
Partnering is an important part of our overall strategy and we are actively talking to potential partners about our innovative pipeline of novel compounds, to ensure these compounds are profiting from the best expertise to bring them to market.
Chairman of the Supervisory Board and Founder
Dieter Willbold studied biochemistry in Tübingen (Germany), Bayreuth (Germany) and Boulder (Colorado, USA). He completed his PhD in 1994 at the University of Bayreuth. After some more years in Bayreuth and a couple of research visits, e.g. at the Sackler School of Medicine of the Tel-Aviv University, he headed a junior research group at the Institute for Molecular Biotechnology in Jena. In 2001 Willbold became an associate Professor at the Heinrich-Heine-University of Düsseldorf. Since 2004, he is full professor at the Institute of Physical Biology at the Heinrich Heine University Düsseldorf. Since 2005, he is additionally director of the Institute of Complex Systems of the Research Centre Jülich.
Director Clinical Development and Founder
Dagmar Jürgens studied Agricultural Sciences at University of Göttingen (Germany) and subsequently earned her PhD at the University of Gießen. She gained experience at national and international levels since 1990, after founding and leading a small and medium-sized biotech enterprise for more than 15 years. In 2006 she changed her focus to Clinical Research and Drug Development. She furthered her experience in Phase II and III Clinical Trials, whilst working at the German Competent Authority (BfArM) and with international Contract Research Organizations. She has been working at the Jülich Research Center since 2011, first at the Technology Transfer Department, and then at the Institute of Complex Systems (ICS-6), where she is the Project Manager for Preclinical and Clinical Research.
Director CMC and Founder
Dr. Adermann has more than 20 years’ experience in peptide therapeutics discovery, translational medicine and clinical development, with a focus on the chemistry, manufacturing and control of novel, peptide active pharmacological ingredients. He holds a PhD in organic chemistry and has co-founded several biotech start-ups, pursuing indications in the fields of antivirals and antibacterials. He was involved in the successful sourcing of seed and round A financing for various start-up companies and has served as managing and scientific director of these ventures. As a consultant in peptide development, he has also supported various preclinical and clinical programs in cardiology, hematology and metabolic diseases. He is an author of more than 90 publications and is a co-inventor of numerous internationally filed patents and patent applications.
Supervisory Board and Founder
Ralph Zahn holds a PhD in natural science from the University of Munich in cooperation with the Max-Planck-Institute for Biochemistry. He received a post-graduate doctors degree from Cambridge University and was for several years an Assistant Professor for Molecular Biology and Biophysics at the ETH Zurich. During his professional career, he was founder and Managing Director of BioSafety GmbH, co-founder and CEO of Alicon AG, a biotechnology enterprise in Zurich, CTO of Biocrates Life Sciences AG in Innsbruck, and Managing Director of Platomics GmbH in Vienna. In October 2014, Ralph Zahn founded Livenity GmbH in Zurich with the aim of marketing visionary technology products in the interface of Personalized Medicine, Digital Health, Bioinformatics and Artificial Intelligence.
Director Preclinical Research and Founder
Antje Willuweit studied Biology at the Technical University of Darmstadt (Germany) and received her PhD from the Max-Planck-Institute in Bad Nauheim (Germany). She gained 9 years of industrial experience in the following Biotech companies: Artemis Pharmaceuticals GmbH, Evotec Neurosciences AG, Evotec AG. In 2011 she joined the Jülich Research Centre at the Institute of Neuroscience and Medicine (INM-4), where she established her own research group. In total, she has got 20 years of experience with animal models in preclinical research, including at least 13 years in the field of preclinical drug testing against Alzheimer´s disease and other neurodegenerative diseases.
Director of Quality Management and Founder,
Gunther Kauselmann studied Biology at the University of Hamburg and completed his PhD at the Center for Molecular Neuroscience Hamburg (ZMNH). In 1998 he joined the startup company Artemis Pharmaceuticals GmbH, which was renamed Taconic Biosciences GmbH after being acquired by Taconic Biosciences Inc. in 2009. At Taconic Dr. Kauselmann held several management positions in scientific operations, quality management and regulatory compliance with increasing responsibility, before being appointed as Vice President of Operations overseeing the entire production process at the Cologne site. During his professional career he also studied Drug Regulatory Affairs at University of Bonn and will receive his Master’s Degree in the autumn of 2017.
- Founding of Priavoid
- Initiation of series A financing
- Basic Research at Forschungszentrum Jülich
- Research funding by Forschungszentrum Jülich, Helmholtz Gesellschaft, HHU Düsseldorf, VW Stiftung